Aptevo Therapeutics (APVO) Retained Earnings (2016 - 2023)
Historic Retained Earnings for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to -$217.5 million.
- Aptevo Therapeutics' Retained Earnings fell 801.96% to -$217.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$217.5 million, marking a year-over-year decrease of 801.96%. This contributed to the annual value of -$206.0 million for FY2022, which is 374.98% up from last year.
- Aptevo Therapeutics' Retained Earnings amounted to -$217.5 million in Q3 2023, which was down 801.96% from -$211.2 million recorded in Q2 2023.
- Over the past 5 years, Aptevo Therapeutics' Retained Earnings peaked at -$139.4 million during Q1 2019, and registered a low of -$221.8 million during Q1 2022.
- Over the past 5 years, Aptevo Therapeutics' median Retained Earnings value was -$193.8 million (recorded in 2022), while the average stood at -$189.0 million.
- Per our database at Business Quant, Aptevo Therapeutics' Retained Earnings plummeted by 5921.12% in 2019 and then skyrocketed by 834.1% in 2023.
- Over the past 5 years, Aptevo Therapeutics' Retained Earnings (Quarter) stood at -$167.9 million in 2019, then fell by 10.57% to -$185.6 million in 2020, then fell by 15.33% to -$214.1 million in 2021, then increased by 3.75% to -$206.0 million in 2022, then dropped by 5.59% to -$217.5 million in 2023.
- Its last three reported values are -$217.5 million in Q3 2023, -$211.2 million for Q2 2023, and -$203.3 million during Q1 2023.